Data Center Infrastructure Drives Record Results for AAON and Stabilis Despite Mixed Backdrop

The Quick Take

• AAON Inc posted 101% Q2 sales growth and 213.6% EPS increase driven by data center cooling demand
• Stabilis Solutions secured a $100M annual data center bridge power deal at record aerospace LNG volumes
• Emergent BioSolutions took a $191M naloxone impairment and cut full-year guidance despite strong core results

Synthesized from 3 sources.

The data center infrastructure buildout continued to generate extraordinary results for companies positioned at the intersection of industrial manufacturing and AI power demands. AAON Inc posted sales growth of 101% in Q2 2026, with adjusted EPS surging 213.6%, driven by acute demand for specialized cooling systems in hyperscaler and enterprise AI data centers. Stabilis Solutions secured a landmark $100 million annual contract to provide bridge power solutions to a major data center operator, partially offsetting a 31% revenue decline from prior-year contract completions. Both results confirm data center-adjacent industrial suppliers are capturing structural demand extending beyond cyclical AI capex.

Emergent BioSolutions' Q2 results present a contrast case: $234 million in revenue and a 41% adjusted EBITDA margin were overshadowed by a $191 million impairment charge related to its naloxone business. The impairment reflects intensifying competition in the opioid reversal market as generic naloxone products have eroded Emergent's pricing power. Management's decision to lower full-year guidance signals naloxone revenue erosion is accelerating faster than previously modeled, creating a bifurcated narrative — strong core biodefense contracts versus an exposed commercial pharma revenue stream under competitive siege.

Investors monitoring data center cooling and industrial infrastructure should track AAON's backlog and gross margin trajectory as production scales, since margin compression from ramp-up costs is a near-term risk. Stabilis Solutions' aerospace LNG volume momentum — record in Q2 — is worth monitoring across the defense sector as hypersonic programs accelerate. For Emergent BioSolutions, resolution of naloxone market positioning strategy and any government contract renewals for biodefense stockpiles will be key events determining whether the stock re-rates higher or faces further impairment risk.